Anti-venom is an important biopharmaceutical product used for treating snake, spider, scorpion and other venoms. It acts as immunoglobulin which helps in neutralizing the toxins or venom in the body. The key applications of anti-venom include zoo and wildlife centers, hospitals and trauma centers.
The Global Anti-Venom Market is estimated to be valued at US$ 9229.16 Mn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the anti-venom market are Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc., and Rare Disease Therapeutics Inc. The increasing cases of snakebites, scorpion stings and spider bites across tropical and subtropical regions is a major factor boosting the demand for anti-venom. The technological advancements in purification methods for anti-venom production is helping key players to provide more targeted and effective treatment options.
Market trends
The rising cases of envenomation is promoting higher investment in anti-venom R&D. Many organizations are focusing on developing novel and affordable anti-venom therapies. The key players are also focusing on capacity and facility expansion to cater to the growing product demand. There is a growing adoption of combination anti-venom therapies for expanding treatment options. Manufacturers are developing lyophilized anti-venom formulations for improved stability and longer shelf-life.
Market Opportunities
The growing health awareness regarding prevention of venomous bites in emerging economies opens significant growth prospects. There is a rise in effective anti-venom stockpiling and availability in primary health centers of tropical regions. This is expected to reduce mortality rates. The scope for developing innovative antibody-based therapies and recombinant anti-venoms presents lucrative opportunities over the forecast period.
Impact of COVID-19 on Anti Venom Market Growth
The COVID-19 pandemic has impacted the growth of the anti venom market. During the initial phase of the pandemic, production and transportation of anti venom were disrupted due to lockdowns and social distancing measures implemented worldwide. Supply chains were affected negatively impacting the availability of anti venom in various regions. This led to a decline in the demand and sales of anti venom in 2020. Various anti venom manufacturing facilities had to suspend their production activities temporarily to adhere to safety guidelines issued by health organizations.
However, the anti venom market is expected to recover steadily post pandemic. With resumption of industrial activities and relaxation of lockdown measures, production and supply of anti venom have started increasing again. The demand is also recovering as healthcare accessibility has improved from 2021 onwards. The anti venom market players are focusing on expanding their production capacities and strengthening supply networks to cater to the increase in requirement. Teleconsultation and online pharmacies have also helped in continuing the sales and distribution of anti venom during the pandemic. However, future waves of COVID-19 infections remains a challenge that needs to be addressed through improved epidemiological understanding and preparedness.
Regions with Concentration of Anti Venom Market Value
The anti venom market in terms of value is currently concentrated highly in North America and Europe. This is due to growing awareness about snake bites and availability of advanced healthcare infrastructure in countries like the United States, United Kingdom, Germany, and France. Large pharmaceutical companies based in these regions actively manufacture different types of anti venom serums for treating envenomations caused by snakes, scorpions and other venomous species found locally. Advancements in biotechnology have also aided in development of highly effective anti venom products attracting higher expenditure.
Fastest Growing Region for Anti Venom Market
The Asia Pacific region is expected to experience the fastest growth in the anti venom market during the forecast period. Countries like India, Indonesia, Thailand and Australia face a high incidence of snake bites annually due to agricultural and outdoor activities in rural areas. With rising incomes, improved access to healthcare and government initiatives for production of affordable anti venom, the demand in the Asia Pacific region is rising rapidly. Local anti venom manufacturers are expanding their presence while collaborating with multinational companies to strengthen the supply and distribution of anti venom therapies.
Sign in to leave a comment.